If amyloid containment rather than production is the operative variable, why have anti-amyloid antibodies (e.g., lecanemab) shown any clinical benefit at all?

Evidence span

If amyloid containment rather than production is the operative variable, why have anti-amyloid antibodies (e.g., lecanemab) shown any clinical benefit at all?

Method & conditions

Evidence type

observational

Method

manual state transition

Conditions

Scope imported from broad Alzheimer's Therapeutics frontier; curator review required.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required